Compare Vanguard Intermediate Term Corporate Bond ETF (VCIT) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Intermediate Term Corporate Bond ETF vs GeneDx Holdings Corp — how do they compare? Vanguard Intermediate Term Corporate Bond ETF trades at $78.48 (market cap $72.20B), while GeneDx Holdings Corp trades at $67.6 (market cap $2.02B). The key difference: Vanguard Intermediate Term Corporate Bond ETF is far larger — about 35.7× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Intermediate Term Corporate Bond ETF for 61 Days and GeneDx Holdings Corp for 19 Days on average.
| VCIT | WGS | |
|---|---|---|
Market Cap | $72.20B | $2.02B |
Volume | 7,532,796 | 734,640 |
Sector | Fixed Income | Health |
52-Week High | $84.82 | $167.51 |
52-Week Low | $77.98 | $34.51 |
Typical Hold Time | 61 Days | 19 Days |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VCIT trades at $78.27 with minimal daily movement (+0.04%). Technical indicators show a bearish trend with strong sell signals from moving averages, though oscillators are neutral. The ETF maintains consistent dividend distributions of $0.34 per share. Recent institutional interest includes Engineers Gate Manager LP's $1.27 million investment and HB Wealth Management's 242.9% position increase in Q3 2026.
VCIT offers a compelling 4.8% yield with low 0.03% expense ratio, positioning it favorably against competitors. However, the bearish technical outlook and interest rate sensitivity present near-term risks. The fund's intermediate-term corporate bond focus provides balanced risk-return profile for income-seeking investors amid economic uncertainty.
GeneDx Holdings Corp. (WGS) trades at $68.53, down 4.18% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported a net loss of $21.02 million for 2025, though Q2 2026 earnings beat expectations. Revenue growth is positive, but profitability remains a challenge with negative margins. Analyst consensus is strongly bullish with a $81.00 price target, supported by recent product launches and institutional interest.
The outlook hinges on execution toward profitability amid high cash burn. Investment opportunity lies in the genomic testing market expansion and analyst optimism, but risks include sustained losses, competitive pressure, and reliance on financing. The stock's trajectory will depend on achieving projected margin improvements and revenue scalability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
